Jun 2026 (Q2 FY26) — Aug 5, 2026
Emergent BioSolutions Q2 FY26 — Strong MCM Performance Offsets Naloxone Headwinds
Read the full callEmergent BioSolutions (EBS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Emergent BioSolutions earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 234 | +66.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -53.4 | −54.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -180 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$6.36 −0.31% · −$0.02
Performance −30.6% 1Y
1Y: $9.16 on 17 Oct 2025 → $6.36. High $13.9 (7 Jan 2026), low $4.45 (11 Aug 2026).
- Previous close
- $6.38
- 52-week range
- $4.45 – $13.9
- One year
- −35.30%
Overview
- Symbol
- EBS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Emergent BioSolutions earnings calls (EBS)
Financials
What the filings say
Net profit, year on year: −1402% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 294 | 195 | 222 | 141 | 231 | 149 | 156 | 234 |
| Operating profit | 65 | -9 | 50 | 2 | 77 | -28 | 11 | -125 |
| Operating margin | 21.9% | −4.9% | 22.5% | 1.1% | 33.1% | −18.8% | 6.7% | −53.4% |
| Other income | 78 | -18 | 43 | -18 | -19 | -23 | 3 | -41 |
| Interest | 8 | 15 | 15 | 15 | 15 | 15 | 11 | 10 |
| Profit before tax | 142 | -28 | 93 | -17 | 58 | -51 | 13 | -166 |
| Tax rate | 19.4% | −13.4% | 26.6% | 28.6% | 11.1% | −7.7% | 49.3% | −8.4% |
| Net profit | 115 | -31 | 68 | -12 | 51 | -55 | 7 | -180 |
| EPS ($ per share) | 2.16 | — | 1.25 | -0.22 | 0.96 | — | 0.13 | -3.49 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 367 | 422 | 727 | 950 | 739 | -22 | -212 | -160 |
| Total liabilities | 1,219 | 1,239 | 1,436 | 1,346 | 1,779 | 1,174 | 907 | 796 |
| Fixed assets | 510 | 542 | 644 | 800 | 818 | 383 | 271 | 205 |
| Total assets | 2,229 | 2,327 | 2,883 | 2,958 | 3,166 | 1,823 | 1,390 | 1,319 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 42 | 188 | 537 | 320 | -34 | -206 | 59 | 171 |
| Cash from investing | -897 | -97 | -152 | -224 | -381 | 212 | 125 | 69 |
| Cash from financing | 789 | -36 | 70 | -141 | 481 | -536 | -190 | -137 |
| Net cash flow | -67 | 56 | 454 | -45 | 66 | -531 | -6 | 104 |
| Capital expenditure | -72 | -87 | -142 | -224 | -116 | -52 | -23 | -14 |
| Free cash flow | -30 | 101 | 395 | 96 | -150 | -258 | 36 | 157 |
Insider filings
59 filings between Nov 7, 2025 and Oct 7, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.26M
15 sales by 6 insiders
73% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
- 22
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 dispositions to the issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| DeGolyer Donald W | — | $443.8K | Oct 7, 2026 |
| Richard Ronald | — | $263.1K | Dec 5, 2025 |
| Dayal Sujata Tyagi | — | $201.1K | May 1, 2026 |
| Zoon Kathryn C | — | $144.5K | May 1, 2026 |
| Katkin Keith | — | $128.2K | Apr 30, 2026 |
| Williams Paul Anthony | — | $78.5K | Oct 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | DeGolyer Donald W Director | Sale 10b5-1 plan | 17,800 | $126.2K |
| Oct 1, 2026 | Williams Paul Anthony SVP, Products Business | Sale 10b5-1 plan | 3,000 | $19.6K |
| Jul 1, 2026 | Williams Paul Anthony SVP, Products Business | Sale 10b5-1 plan | 3,000 | $25.2K |
| Jun 8, 2026 | Williams Paul Anthony SVP, Products Business | Tax withheld | 694 | $5.6K |
| Jun 8, 2026 | LINDAHL RICHARD S EVP, Chief Financial Officer | Tax withheld | 3,964 | $31.7K |
| Jun 8, 2026 | Hartzel William SVP, Bioservices | Tax withheld | 1,741 | $13.9K |
| Jun 8, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Tax withheld | 2,018 | $16.1K |
| May 1, 2026 | Dayal Sujata Tyagi Director | Sale 10b5-1 plan | 12,781 | $106.8K |
| May 1, 2026 | Zoon Kathryn C Director | Sale 10b5-1 plan | 16,145 | $135.0K |
| May 1, 2026 | DeGolyer Donald W Director | Sale 10b5-1 plan | 954 | $8.5K |
| May 1, 2026 | DeGolyer Donald W Director | Sale 10b5-1 plan | 14,527 | $121.4K |
| May 1, 2026 | Dayal Sujata Tyagi Director | Sale 10b5-1 plan | 980 | $8.8K |
| May 1, 2026 | Zoon Kathryn C Director | Sale 10b5-1 plan | 1,057 | $9.5K |
| Apr 30, 2026 | Dayal Sujata Tyagi Director | Award 10b5-1 plan | 25,344 | $0 |
| Apr 30, 2026 | Harsanyi Zsolt Chairman | Award | 25,344 | $0 |
| Apr 30, 2026 | Katkin Keith Director | Sale 10b5-1 plan | 15,481 | $128.2K |
| Apr 30, 2026 | Katkin Keith Director | Award 10b5-1 plan | 25,344 | $0 |
| Apr 30, 2026 | FOWLER JOHN D JR Director | Award | 25,344 | $0 |
| Apr 30, 2026 | Zoon Kathryn C Director | Award 10b5-1 plan | 25,344 | $0 |
| Apr 30, 2026 | DeGolyer Donald W Director | Award 10b5-1 plan | 25,344 | $0 |
| Apr 30, 2026 | White Marvin L Director | Award | 25,344 | $0 |
| Apr 30, 2026 | Fowler Neal Franklin Director | Award | 25,344 | $0 |
| Apr 30, 2026 | Richard Ronald Director | Award | 25,344 | $0 |
| Apr 29, 2026 | LINDAHL RICHARD S EVP, Chief Financial Officer | Award | 162,680 | $0 |
| Apr 29, 2026 | Lowry Simon C SVP, R&D, CMO | Award | 100,111 | $0 |
| Apr 29, 2026 | Perl Jessica SVP, General Counsel, Corp Sec | Award | 104,282 | $0 |
| Apr 29, 2026 | Hartzel William SVP, Bioservices | Award | 100,111 | $0 |
| Apr 29, 2026 | Williams Paul Anthony SVP, Products Business | Award | 100,111 | $0 |
| Apr 29, 2026 | PAPA JOSEPH C President and CEO | Award | 187,708 | $0 |
| Apr 29, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Award | 100,111 | $0 |
| Apr 1, 2026 | Williams Paul Anthony SVP, Products Business | Sale 10b5-1 plan | 4,000 | $33.8K |
| Mar 5, 2026 | LINDAHL RICHARD S EVP, Chief Financial Officer | Tax withheld | 23,650 | $199.6K |
| Mar 5, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Tax withheld | 8,199 | $69.2K |
| Mar 5, 2026 | Lowry Simon C SVP, R&D, CMO | Tax withheld | 10,636 | $89.8K |
| Mar 5, 2026 | PAPA JOSEPH C President and CEO | Tax withheld | 37,055 | $312.7K |
| Mar 5, 2026 | Hartzel William SVP, Bioservices | Tax withheld | 9,493 | $80.1K |
| Mar 5, 2026 | Williams Paul Anthony SVP, Products Business | Tax withheld | 9,397 | $79.3K |
| Mar 5, 2026 | Perl Jessica SVP, General Counsel, Corp Sec | Tax withheld | 6,465 | $54.6K |
| Mar 3, 2026 | FOWLER JOHN D JR Director | Award | 5,006 | $45.0K |
| Mar 1, 2026 | Williams Paul Anthony SVP, Products Business | Tax withheld | 116 | $945 |
| Mar 1, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Tax withheld | 313 | $2.6K |
| Mar 1, 2026 | LINDAHL RICHARD S EVP, Chief Financial Officer | Tax withheld | 683 | $5.6K |
| Feb 9, 2026 | Perl Jessica SVP, General Counsel, Corp Sec | Tax withheld | 918 | $10.1K |
| Feb 6, 2026 | Hartzel William SVP, Bioservices | Tax withheld | 630 | $6.9K |
| Feb 6, 2026 | LINDAHL RICHARD S EVP, Chief Financial Officer | Disposition to issuer | 46,155 | $504.0K |
| Feb 6, 2026 | Hartzel William SVP, Bioservices | Disposition to issuer | 5,771 | $63.0K |
| Feb 6, 2026 | Williams Paul Anthony SVP, Products Business | Tax withheld | 1,022 | $11.2K |
| Feb 6, 2026 | Williams Paul Anthony SVP, Products Business | Disposition to issuer | 8,655 | $94.5K |
| Feb 6, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Tax withheld | 2,852 | $31.1K |
| Feb 6, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Disposition to issuer | 28,847 | $315.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Emergent BioSolutions Inc.
Free account. Everything above stays public.
Write why you follow Emergent BioSolutions Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading